ELAN — Elanco Animal Health Share Price
Last trade - 00:00- $11.47bn
- $14.95bn
- $4.72bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 21.62 | ||
| PEG Ratio (f) | 0.25 | ||
| EPS Growth (f) | 631.47% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.75 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 40.4 | ||
| Price to Sales | 2.43 | ||
| EV to EBITDA | 21.51 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.74% | ||
| Return on Equity | -3.67% | ||
| Operating Margin | -4.35% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4,764 | 4,411 | 4,417 | 4,439 | 4,715 | 5,001.54 | 5,266.99 | 7.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +13.47 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
Directors
- R. David Hoover CHM (75)
- Jeffrey Simmons PRE (53)
- Todd Young CFO (49)
- Racquel Mason EVP (51)
- David Kinard EVP (54)
- Ramiro Cabral EVP (49)
- Ellen de Brabander EVP
- Dirk Ehle EVP (51)
- Joyce Lee EVP (48)
- Jose Manuel Simas EVP (53)
- David Urbanek EVP (54)
- James Meer CAO (51)
- Kapila Anand IND (67)
- John Bilbrey IND (65)
- William Doyle IND (59)
- Scott Ferguson IND (47)
- Art Garcia IND (60)
- Michael Harrington IND (58)
- Paul Herendeen IND (65)
- Deborah Kochevar IND (64)
- Lawrence Kurzius IND (63)
- Kirk McDonald IND (54)
- Denise Scots-Knight IND (61)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- May 3rd, 2018
- Public Since
- September 20th, 2018
- No. of Shareholders
- 167
- No. of Employees
- 9,400
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 497,168,077
- Address
- 450 ELANCO CIRCLE, INDIANAPOLIS, 46221
- Web
- https://www.elanco.com/
- Phone
- Auditors
- Ernst & Young LLP
Latest News for ELAN
Upcoming Events for ELAN
Q1 2026 Elanco Animal Health Inc Earnings Release
Elanco Animal Health Inc Annual Shareholders Meeting
Q2 2026 Elanco Animal Health Inc Earnings Release
Similar to ELAN
Abbvie
New York Stock Exchange
AstraZeneca
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
FAQ
As of Today at 02:24 UTC, shares in Elanco Animal Health are trading at $23.08. This share price information is delayed by 15 minutes.
Shares in Elanco Animal Health last closed at $23.08 and the price had moved by +114.3% over the past 365 days. In terms of relative price strength the Elanco Animal Health share price has outperformed the S&P500 Index by +75.68% over the past year.
The overall consensus recommendation for Elanco Animal Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreElanco Animal Health does not currently pay a dividend.
Elanco Animal Health does not currently pay a dividend.
Elanco Animal Health does not currently pay a dividend.
To buy shares in Elanco Animal Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $23.08, shares in Elanco Animal Health had a market capitalisation of $11.47bn.
Here are the trading details for Elanco Animal Health:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ELAN
Based on an overall assessment of its quality, value and momentum Elanco Animal Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Elanco Animal Health is $29.58. That is 28.16% above the last closing price of $23.08.
Analysts covering Elanco Animal Health currently have a consensus Earnings Per Share (EPS) forecast of $1.03 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Elanco Animal Health. Over the past six months, its share price has outperformed the S&P500 Index by +14.5%.
As of the last closing price of $23.08, shares in Elanco Animal Health were trading +11.87% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Elanco Animal Health PE ratio based on its reported earnings over the past 12 months is 21.62. The shares last closed at $23.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Elanco Animal Health's management team is headed by:
- R. David Hoover - CHM
- Jeffrey Simmons - PRE
- Todd Young - CFO
- Racquel Mason - EVP
- David Kinard - EVP
- Ramiro Cabral - EVP
- Ellen de Brabander - EVP
- Dirk Ehle - EVP
- Joyce Lee - EVP
- Jose Manuel Simas - EVP
- David Urbanek - EVP
- James Meer - CAO
- Kapila Anand - IND
- John Bilbrey - IND
- William Doyle - IND
- Scott Ferguson - IND
- Art Garcia - IND
- Michael Harrington - IND
- Paul Herendeen - IND
- Deborah Kochevar - IND
- Lawrence Kurzius - IND
- Kirk McDonald - IND
- Denise Scots-Knight - IND